ストックスクリーナーアプリを入手
175.58
2.37%
4.06
アフターアワーズ：
175.00
-0.58
-0.33%
Abbvie Inc (ABBV) 最新ニュース
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally - The Motley Fool
Abbvie - Contract Pharma
AbbVie (NYSE:ABBV) Stock Price Up 2%Here's What Happened - MarketBeat
AbbVie, Novartis and drug industry win court battle in larger 340B war - Crain's Chicago Business
Alembic Pharma Gains USFDA Approval for Epilepsy Treatment - Devdiscourse
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AI & Data Convergence - AbbVie
AbbVie (NYSE:ABBV) Trading Down 0.5% After Insider Selling - MarketBeat
AbbVie acquiring Madison-based Nimble Therapeutics for $200 million - Milwaukee Journal Sentinel
AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline - Kilgore News Herald
Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now? - Insider Monkey
Acellular Dermal Matrices Market Projected To Witness Substantial Growth, 2024-2031: Stryker Corporation, - EIN News
Abbvie SVP Kevin Buckbee sells stock for $310,032 - Investing.com India
Kevin K. Buckbee Sells 1,800 Shares of AbbVie Inc. (NYSE:ABBV) Stock - MarketBeat
ASH: AbbVie/Genmab Look To Stake Anti-CD20 Bispecific Claim In CLL - Citeline News & Insights
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novartis, AbbVie Score Win to Block West Virginia Drug Limit Law - Bloomberg Law
AbbVie's SWOT analysis: biopharma giant navigates post-Humira landscape - Investing.com
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie Inc. (NYSE:ABBV) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Biologics Market to See Booming Growth 2024-2031 | AbbVie Inc., - openPR
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie's (ABBV) Overweight Rating Reiterated at Piper Sandler Companies - MarketBeat
Bain Sued Over Cerevel Trades Before $8.7 Billion Sale to AbbVie - Bloomberg Law
AbbVie (NYSE:ABBV) Price Target Raised to $220.00 at Piper Sandler - MarketBeat
4 Big Drug Stocks That May Continue to Outperform in 2025 - Yahoo Finance
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? - Yahoo! Voices
Spinal Cord Injury Therapeutics Market Set to Witness Significant Growth by 2024-2031: AbbVie Inc, Pfizer - EIN News
Immunology Market Huge Growth in Future Scope 2024-2031 | AbbVie - openPR
Is AbbVie Ready for a Bullish Turn? - Investing.com
Botulinum Toxin in Urology Market Top PlayersAbbVie Inc., Merz Pharma; Ipsen Pharma; GALDERMA; Allergan PLC. - openPR
AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish - MSN
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Why Investors Should Watch AbbVie Inc (ABBV) - See It Market
AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors - Seeking Alpha
AbbVie (ABBV) Acquires Nimble Therapeutics for $200 Million - GuruFocus.com
AbbVie Enters Oversold Territory - Forbes
AbbVie, Novartis Drop Suit Over Kansas Drug Discount Limit Law - Bloomberg Law
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock? - Yahoo Finance
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline - Yahoo Finance
AbbVie continues deal-making spree with $200M Nimble buy - PharmaLive
AbbVie Continues Deal-Making Spree With $200M Nimble Buy - BioSpace
AbbVie adds psoriasis med with Nimble takeover - pharmaphorum
AbbVie to acquire Nimble Therapeutics for $200m - Yahoo Finance
Alzheimers Drugs Market to See Booming Growth 2024-2031 | - openPR
AbbVie to acquire Nimble Therapeutics in $200m deal - World Pharmaceutical Frontiers
AbbVie Parkinson’s Drug Rejected by FDA After Plant Inspection - MSN
AbbVie Inc. (NYSE:ABBV) Stock Position Lowered by Lord Abbett & CO. LLC - MarketBeat
B. Riley Wealth Advisors Inc. Decreases Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie (ABBV) Announces Leadership Transition in Financial Department - GuruFocus.com
AbbVie nabs autoimmune diseases specialist Nimble - The Pharma Letter
AbbVie to buy Madison pharmaceutical tech firm for $200 million - The Business Journals
AbbVie buying Wisconsin biotech company Nimble Therapeutics for $200 million - The Business Journals
AbbVie (NYSE:ABBV) Stock Price Up 0.1%Still a Buy? - MarketBeat
This Drugmaker's (ABBV) Parkinson's Medication Just Cleared A Key Hurdle – Is It Primed For A Monster Year In 2025? - Yahoo Finance
AbbVie to acquire Wisconsin biopharma for $200 million - Crain's Chicago Business
AbbVie Inc. entered into a definitive agreement to acquire Nimble Therapeutics, Inc. from Telegraph Hill Partners and Roche Venture Fund for $200 million. - Marketscreener.com
AbbVie to acquire Roche spinout Nimble in immune drug deal - BioPharma Dive
Oddo BHF Asset Management Sas Takes Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Retirement Systems of Alabama Lowers Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Buying Nimble Therapeutics for $200 Million to Boost Immunology Pipeline - Marketscreener.com
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline - PR Newswire
Interstitial Cystitis Drugs Market CAGR of 6.9% Size, Share, and Growth Forecast 2024-2031 | AbbVie Inc., - EIN News
Franklin Resources Inc. Cuts Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Peapack Gladstone Financial Corp - MarketBeat
AbbVie (NYSE:ABBV) Shares Down 0.1%Should You Sell? - MarketBeat
0.62%
1.48%
大文字化:
|
ボリューム (24 時間):